Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice
Journal of Diabetes Investigation · 2024
DOI: 10.1111/jdi.14287 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Diabetes Investigation, 2024. Verfasst von Yuichiro Yamada und 7 weiteren Autor:innen. Beteiligte Einrichtung: Japan Association for Diabetes Education and Care, Tokyo, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucosides, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kowa Company, Ltd, Kowa Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims/Introduction Sodium–glucose cotransporter 2 (SGLT2) inhibitors effectively and safely reduce fasting and postprandial hyperglycemia while promoting weight loss. However, their unique mechanism of action contributes to concerns regarding their safety. We therefore carried out a large‐scale, non‐commercial, investigator‐initiated study on the safety and effectiveness of the SGLT2 inhibitor tofogliflozin. Materials and Methods This multicenter, open‐label, uncontrolled, prospective observational study was carried out at hospitals and clinics across Japan in participants aged ≥20 years who were SGLT2 inhibitor‐naïve and had an established diagnosis of type 2 diabetes. The primary endpoint was adverse drug reactions (ADRs) of special interest. Secondary endpoints included all other ADRs and adverse events, glycated hemoglobin (HbA1c), and weight loss. Results The study, carried out from June 2014 through February 2020, enrolled 11,480 participants from 1,103 medical institutions; 6,967 participants completed the 104‐week follow up. The most common ADRs of special interest were urinary and genital tract infections (1.53%), followed by volume depletion (1.25%). Hypoglycemia occurred in 27 participants (0.24%), adverse events in 1,054 (9.18%) and ADRs in 645 (5.62%). HbA1c decreased by 0.85% (95% confidence interval 0.82%–0.88%) and bodyweight decreased by 3.05 kg (95% confidence interval 2.94–3.17 kg). The HbA1c target was achieved by 51.70% of participants for target HbA1c
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Japan Association for Diabetes Education and Care, Tokyo, Japan.
- Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan.
- Kansai Electric Power Hospital, Osaka, Japan.
- Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.
- Center for One Medicine Innovative Translational Research, Gifu University, Gifu, Japan.
- Department of Metabolism and Clinical Nutrition, Kyoto University Hospital, Kyoto, Japan.
ORCID-Profile: Yuichiro Yamada, Daisuke Yabe, Yutaka Seino
Förderung
- Kowa Company, Ltd
- Kowa Company
Zitieren
APA
Yamada, Y., Yabe, D., Shide, K., Suzuki, A., Terauchi, Y., Sato, Y., Shihara, N., & Seino, Y. (2024). Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14287
Vancouver
Yamada Y, Yabe D, Shide K, Suzuki A, Terauchi Y, Sato Y, et al. Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice. Journal of Diabetes Investigation. 2024. doi:10.1111/jdi.14287
BibTeX
@article{Yamada2024,
author = {Yamada, Yuichiro and Yabe, Daisuke and Shide, Kenichiro and Suzuki, Atsushi and Terauchi, Yasuo and Sato, Yasunori and Shihara, Nobuyuki and Seino, Yutaka},
title = {Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice},
journal = {Journal of Diabetes Investigation},
year = {2024},
doi = {10.1111/jdi.14287}
}
EUVIMED